Apply for the BioTarget cancer therapy competition and win free lab experimentation

Friday, March 1, 2019 @ 12:15 pm

BioTarget is a global biotech competition aimed at identifying and supporting those working on new molecules for cancer therapy. Research groups with entrepreneurial ambitions and young biotech companies can submit a proposal by March 29th. The shortlisted candidates will be invited for a pitch event in London, UK, and the three winners will receive free experimentation worth up to $100,000 in Europe’s leading robotic cloud lab to reach their next milestone.

One in two people will be diagnosed with cancer during their lifetime. BioTarget is the world’s first biotech competition for emerging companies dedicated to finding new molecules for cancer treatment.
The competition invites applications from early ventures seeking to characterise further or validate their drug targets using cellular and molecular assays. Following the online application, the top 10 applicants will be invited to attend the pitch event in London, where they will present their projects in front of an expert panel and a diverse audience consisting of life science investors, industry professionals, academics, and fellow entrepreneurs.

Why apply
Win free experimentation worth up to $100,000 conducted in Arctoris’ cloud lab equal to one year of lab work.
In addition to free experimentation, the three winners will benefit from the BioTarget partners’ business support. This means free IP training, hands-on business mentoring from experienced entrepreneurs and executives, and access to a leading network of bio-entrepreneurs and investors.

Timeline

March 29th Application deadline
April 15th Announcements
Late May Pitch event in London

Prizes
1st prize: free experiments worth $100k
2nd prize: free experiments worth $50k
3rd prize: free experiments worth $20k

Publicity & Network
Get your company promoted to an exclusive audience through all Science Entrepreneur Club channels (article, interview and more).
Become part of a unique network and get the opportunity to connect to investors, industry professionals and fellow entrepreneurs.

Apply now

You may also be interested in

Swiss Biotech Report 2024 shows sector performing well in 2023 by continuing to embrace international alliances

Record revenues of CHF 7.3 billion (USD 8.1 billion) – Capital investments increase by more than 50% to CHF 2 billion – CHF 1.4 billion by public companies, CHF 0.6 billion by private companies – Significant licensing and M&A activity in 2023 – VectivBio, T3, Vertex, Santhera – R&D investments of publicly traded biotech companies have decreased in line with global markets, wherea
April 23, 2024

SOTIO enters into agreement with Biocytogen to expand antibody-drug conjugates pipeline

Option and license agreement includes multiple fully human bispecific antibodies generated with Biocytogen’s proprietary RenLite platform Agreement will enable SOTIO to significantly broaden its next-generation ADC portfolio, including multi-specific ADCs Biocytogen will receive an upfront payment and potential development milestone payments totaling up to $325.5 million
July 16, 2024

Asceneuron secures USD 100 million financing to advance therapeutics in neurodegenerative diseases

Financing led by Novo Holdings, including new investment from EQT Life Sciences – LSP Dementia Fund, OrbiMed and SR One with participation from existing investors M Ventures, Sofinnova Partners, GSK Equities Investments Limited and Johnson & Johnson Innovation – JJDC, Inc. Funds will be used to progress lead asset ASN51, an oral small molecule OGA inhibitor, into Phase 2 clinical developme
July 16, 2024

LimmaTech appoints Staph Leavenworth Bakali as Chairman of the Board

LimmaTech Biologics AG, a clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases, today announced the appointment of Staph Leavenworth Bakali as independent Chairman of its Board of Directors. Mr. Leavenworth Bakali brings over 30 years of senior executive and board-level experience in the life science and healthcare industries.
July 1, 2024

Newron flash update “A pivotal year” - potential of schizophrenia drug

June 27, 2024

Ymmunobio and EVIIVE: Collaboration to develop advanced liquid biopsy for cancer patients

Ymmunobio and EVIIVE are pleased to announce their strategic collaboration to develop an innovative liquid biopsy technology utilizing extracellular vesicles (EVs). This partnership marks a significant advancement in precision medicine, aiming to enhance disease detection and patient monitoring accuracy and efficacy.
June 24, 2024